cerca CERCA
Lunedì 21 Giugno 2021
Aggiornato: 09:33
Temi caldi


European Hematology Association - Daratumumab Maintenance Improves Progression-Free Survival After Autologous Stem Cell Transplantation in Multiple Myeloma Patients

THE HAGUE, Netherlands, June 12, 2021 /PRNewswire/ -- Part 1 of the CASSIOPEIA phase-3 study compared the addition of daratumumab to bortezomib, thalidomide, and dexamethasone (D-VTd) induction/consolidation with VTd alone in transplant-eligible patients with newly diagnosed multiple myeloma. The results of the study showed superior efficacy of D-VTd over VTd alone in combination with autologous stem cell transplantation (ASCT), which led to the regulatory approval of the treatment. Here, we pres...

European Hematology Association - Genetic Modification of Autologous Hematopoietic Stem Cells: A Potential Treatment for Mucopolysaccharidosis Type I Hurler

THE HAGUE, Netherlands, June 11, 2021 /PRNewswire/ -- Mucopolysaccharidosis type I Hurler (MPS-IH) is caused by a deficiency in alpha-L-iduronidase (IDUA) and is typically managed by allogeneic hematopoietic stem cell (HSC) transplantation, which has shown high rates of success when patients are treated at a young age. However, skeletal abnormalities remain and progressive neurocognitive deterioration over time severely affect a patient's quality of life. In this first-in-human phase I/II clinica...

CGTN: Peng Liyuan calls for global efforts in AIDS and TB prevention and treatment

BEIJING, June 8, 2021 /PRNewswire/ -- Peng Liyuan, wife of Chinese President Xi Jinping, called on people from all walks of life in all countries to join hands and take action to strengthen the prevention and treatment of AIDS and tuberculosis (TB), in order to benefit all mankind and build a global community of health for all.

Semaglutide in people with obesity: boosts wellbeing and ability to perform daily physical activities

BAGSVÆRD, Denmark, May 13, 2021 /PRNewswire/ -- Novo Nordisk today announced new results from the STEP phase 3a clinical trial programme, demonstrating potential benefits beyond weight loss for people with obesity being treated with semaglutide 2.4 mg. The trial showed that treatment with once-weekly semaglutide 2.4 mg led to significant improvements in physical functioning, such as climbing stairs and tying your shoes, and beneficial effects on weight related and health related quality of life s...

Xinhua Silk Road: China's WELLE Group expects new development in wet garbage treatment

BEIJING, April 27, 2021 /PRNewswire/ -- As more efforts are being made on waste sorting in China, WELLE Group, one of China's leading enterprises in the field of wet garbage treatment, has achieved an outstanding sales performance in 2020 with revenue up 17.29 percent year on year and cash flow from operating activities exceeding 363 million yuan.

Aion Therapeutic Files 4 New Patent Applications (Including for the Treatment of Human Cancers)

TORONTO, March 11, 2021 /PRNewswire/ -- Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") announced today that it has filed 4 new patent applications related to preparations of medicinal and psychedelic mushrooms. The patent applications include use of medicinal mushrooms for the treatment of human cancers including breast cancer, use of combination medical cannabis and medicinal mushroom preparations for the treatment of interstitial cystitis and other bladder diseases, and...

Femtech startup OCON Healthcare announces last patient in phase IIa clinical study, evaluating its intrauterine drug delivery platform IUB™ SEAD™, a non-invasive treatment for abnormal uterine bleeding (AUB)

The trial assesses the safety and efficacy of the IUB™ SEAD™, a disruptive treatment for AUB. In this study, 50% of the participating patients have reached the End of the Study point, demonstrating a significant reduction in bleeding, avoiding the need to undergo invasive uterine ablation procedures or even a hysterectomy

T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immunotherapy

THE HAGUE, Netherlands, Feb. 3, 2021 /PRNewswire/ -- T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to ...

Hanmi Pharmaceutical expects U.S. FDA approval for 2 new drugs

SEOUL, South Korea, Jan. 18, 2021 /PRNewswire/ -- Hanmi Pharmaceutical Co., Ltd. plans to create a global R&D achievement based on innovations of inflammation–fibrosis treatment, Triple-acting new drug for NASH (non-alcoholic steatohepatitis) treatment as well as various other innovations in metabolic disease, oncology and rare disease fields.

TricValve® Transcatheter Bicaval Valves System granted Designation as Breakthrough Device by the U.S. Food and Drug Administration (FDA)

VIENNA, Dec. 22, 2020 /PRNewswire/ -- P+F Products + Features GmbH has been granted designation as a Breakthrough Device for the company's lead product, the TricValve® Transcatheter Bicval Valves System by the U.S. Food & Drug Administration on December 15th 2020. The TricValve® is a system of two self-expanding biological valves for the treatment of patients with hemodynamically relevant tricuspid insufficiency and caval reflux. "The TricValve® system represents a new technology offering a  pote...

The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention

GENEVA and CASTRES , France, Dec. 14, 2020 /PRNewswire/ -- The EspeRare Foundation and the Pierre Fabre group announced today that they have entered into a license and development collaboration agreement for the development and commercialization of ER-004, a prenatal treatment for XLHED (X-linked Hypohidrotic Ectodermal Dysplasia), a rare, debilitating congenital disease. The next clinical study is expected to start in 2021 and will aim at qualifying and registering what may become the first appr...

Obiltoxaximab Receives Marketing Authorization From European Commission For The Treatment Of Inhalation Anthrax

PARSIPPANY, N.J., Dec. 2, 2020 /PRNewswire/ -- Elusys Therapeutics, Inc. (Elusys) today announced that the European Commission has approved obiltoxaximab, the company's monoclonal antibody (mAb) anthrax antitoxin for the treatment of inhalation anthrax. Obiltoxaximab is indicated in all age groups in combination with appropriate antibacterial drugs for the treatment of inhalational anthrax due to Bacillus anthracis; and for post-exposure prophylaxis of inhalational anthrax when alternative therap...

MedAlliance announces successful completion of enrolment in ISABELLA clinical trial for the treatment of failing AV fistulas in hemodialysis patients

NYON, Switzerland, Nov. 25, 2020 /PRNewswire/ -- MedAlliance has announced completion of patient enrolment in the ISABELLA Clinical Trial with SELUTION SLR™ 018 DEB (drug-eluting balloon) for the treatment of dysfunctional AV fistulas in end-stage renal failure patients undergoing hemodialysis. SELUTION SLR (Sustained Limus Release) is a novel sirolimus-eluting balloon that provides a controlled sustained release of drug, similar to a drug-eluting stent (DES).

ora in
Prima pagina
in Evidenza